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Edited by Michael R. BubbAbstract Based on the enzyme speciﬁcity of matriptase, a type
II transmembrane serine protease (TTSP) overexpressed in epi-
thelial tumors, we screened a cDNA library expressing variants
of the protease inhibitor eglin c in order to identify potent
matriptase inhibitors. The most potent of these, R1K
0
4-eglin,
which had the wild-type Pro45 (P1 position) and Tyr49 (P4 0 posi-
tion) residues replaced with Arg and Lys, respectively, led to the
production of a selective, high aﬃnity (Ki of 4 nM) and proteo-
lytically stable inhibitor of matriptase. Screening for eglin c vari-
ants could yield speciﬁc, potent and stable inhibitors to
matriptase and to other members of the TTSP family.
 2006 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
Keywords: Matriptase; Eglin c; Serine protease; Enzyme
inhibition1. Introduction
The type II transmembrane serine proteases (TTSPs) are an
emerging class of cell surface proteolytic enzymes. Matriptase,
one the most extensively studied member of this family, has the
broadest expression pattern of all the TTSPs, being detected in
a wide range of human tissues [1]. Although studies of knock-
out mice have revealed that matriptase is involved in the devel-
opment of the epidermis, hair follicles, and cellular immune
system [2], very few in vivo substrates for this enzyme have
been identiﬁed. It has been suggested that matriptase could
play important roles in tumor cell metastasis and invasiveness
[3–9]. Indeed, this enzyme causes malignant transformation
when orthotopically overexpressed in the skin of mice thus
suggesting the causal role of matriptase in human carcinogen-
esis [9]. Other members of the TTSPs, such as Tmprss2 [10],
Tmprss3 [11] and hepsin [12], have also been implicated in can-
cer. Thus, matriptase, and the TTSPs in general, are poten-
tially interesting therapeutic targets.
Recently, it was demonstrated that potent inhibitors for fur-
in and kexin, members of the proprotein convertases family
[13], could be produced by introduction of furin or kexin rec-
ognition sequences within the reactive site of the proteaseAbbreviations: TTSP, Type II transmembrane serine protease; IMAC,
immobilized metal-chelate aﬃnity chromatography; MUGB, 4-meth-
ylumbelliferyl p-guanidino benzoate; HAT, human airway trypsin-like
protease; AMC, 7-amino-4-methylcoumarin
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dimensional structure of eglin c have found that optimization
of interaction between enzyme and inhibitor could be ad-
dressed by screening eglin c cDNA libraries containing ran-
domly substituted residues within projected adventitious
contact sites outside the reactive site [16]. The similarity in
speciﬁcity between matriptase and furin, which preferentially
recognizes the R–X–X–R (P4 to P1 position) sequence [17],
led us to the hypothesis that matriptase and other members
of the TTSP family could be targets of genetically engineered
variants of serine protease inhibitors such as eglin c.
In the present study, we were able to produce eglin c variants
that exhibit strong and selective inhibition against matriptase
by mutagenesis of amino acids in and outside the inhibitor’s
reactive site loop. We demonstrate that the eglin c protein
could be used as a macromolecular scaﬀold to develop potent
and selective inhibitors for matriptase and to a larger extent
for all the members of the expanding TTSP family.2. Materials and methods
2.1. Materials
Matriptase cDNA was a generous gift from Dr. Chen-Yong Lin
(Georgetown University, Washington, USA). Puriﬁed recombinant
human airway trypsin-like protease (HAT) was a generous gift from
Dr. Manabu Chokki (Teijin Pharma Limited, Tokyo, Japan). Wild-
type synthetic eglin c (termed L1-eglin), R1-eglin, K2R1-eglin and
R4R1-eglin cDNA constructions as well as the Y49X-eglin cDNA li-
brary were a generous gift of Dr. Robert S. Fuller (University of Mich-
igan, Ann Arbor, USA).
2.2. Construction, expression and puriﬁcation of matriptase 596–855
Nucleotides corresponding to amino acids 596–855 of matriptase
were ampliﬁed by PCR, ligated into the pQE-30 vector and trans-
formed in Escherichia coliM15 strain (Qiagen, Mississauga, Ont., Can-
ada). Expression was induced for 4 h at 37 C with 0.5 mM IPTG
(Promega, Madison, WI, USA). Bacterial cells were harvested, resus-
pended in lysis buﬀer (50 mM Tris–HCl, pH 8, 500 mM KCl, 10%
glycerol, 1 mM b-mercaptoethanol), sonicated and centrifuged at
10000 · g for 15 min. The pellet was solubilized in 6 M urea. Proteins
were puriﬁed using immobilized metal-chelate aﬃnity chromatography
(IMAC). Fractions were pooled and dialysed overnight at 4 C against
50 mM Tris (pH 9), 10% glycerol, 3 M urea and 1 mM b-mercap-
toethanol. Proteins were dialysed for 6 h at 4 C against 50 mM Tris
(pH 9), 10% glycerol, 1 mM b-mercaptoethanol. Matriptase was fur-
ther puriﬁed using Mono-Q ion exchange chromatography on an Ex-
plorer system (Amersham Biosciences, Baie d’Urfe´, Que., Canada).
2.3. General kinetic methods
Enzyme activities were monitored by measuring the release of ﬂuo-
rescence from AMC-coupled peptides (excitation, 360 nm; emission,
441 nm) in a FLX-800 TBE microplate reader (Bio-Tek Instruments,
Winooski, VT, USA). The puriﬁed human matriptase was active-
site titrated with the burst titrant 4-methylumbelliferyl-p-guanidinoblished by Elsevier B.V. All rights reserved.
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in Tris–HCl 100 mM containing 500 lg/ml BSA at pH 9. Human sol-
uble furin was expressed, puriﬁed, titrated and assayed as described
previously [18]. The puriﬁed HAT protein was active-site titrated with
MUGB. Assays with HAT were performed in Tris–HCl 50 mM at pH
8.6.2.4. Construction, expression and puriﬁcation of eglin c variants
Wild-type synthetic eglin c protein, (also termed L1-eglin in Ref. [14]
or WT-eglin herein), R1-eglin, K2R1-eglin and R4R1-eglin construc-
tions were described previously [14]. In essence, WT-eglin is a protein
product produced from a synthetic gene optimized for prokaryotic
expression where the three N-terminal residues (Met1-Ser-Met) diﬀer
in sequence from that of the naturally occurring eglin c (Thr1-Gly-
Phe). All eglin c variants studied herein are protein products of the
optimized (Met-Ser-Met) construct. R4R1E
0
4-eglin, R4R1K
0
4-eglin and
R4R1R
0
4-eglin were recovered from the rapid screening of matriptase
inhibition by the Y49X library (see below). R1K
0
4-eglin was obtained
by substitution of the tyrosine 49 for a lysine in the R1-eglin construc-
tion using the Quickchange II mutagenesis kit (Stratagene, La Jolla,
CA, USA) as described by the manufacturer. All eglin c variants were
transformed into bacterial host strain BL21-(DE3) pLys (Novagen,
Madison, WI, USA) and the expression and puriﬁcation was per-
formed as described [14].2.5. Screening of eglin c Y49X library
A cDNA eglin c variant library, in which all three nucleotides of the
codon corresponding to residue 49 were fully randomized [16], was
used to screen for matriptase inhibition. This library, termed Y49X,
was transformed into bacterial host strain BL21-(DE3) pLys. Trans-
formants were grown in 200 ll of LB containing kanamycin (50 lg/
ml) at 37 C in 96-well, 0.45-lm GHP membrane ﬁlter plates (Pall Life
Sciences, Ville St.-Laurent, Que., Canada). When OD600 values
reached 0.4, expression was induced for 4 h with 1 mM IPTG in the ﬁl-
ter plate (before IPTG addition, 60 ll of culture was removed and
transferred to a 96-well master plate in which 60 ll of a 50% glycerol
solution was added to each well for storage at 80 C). Puriﬁcation
of eglin c variants was performed as described [16]. Partially puriﬁed
eglin c variants (10 ll) were pre-incubated with matriptase (4 nM)
for 15 min at room temperature in a 96-well plate (Corning, Acton,
MA, USA). Residual matriptase activity was recorded after 30 min
of incubation with Boc-Glu-Glu-Arg-AMC. Vectors encoding selected
variants were recovered from master plates and sequenced. Interesting
variants were puriﬁed to homogeneity (as described earlier) on a 50 ml
scale for further characterization.2.6. Inhibition assays
Enzymes were diluted to concentration ranging from 4 to 12.5 nM
for furin, from 2 to 7 nM for matriptase and 20 pM for HAT and incu-
bated with appropriate dilutions of the eglin c variants for 15 min at
room temperature. Residual enzyme activity was measured by follow-
ing the hydrolysis of a ﬂuorogenic substrate (4 lM Boc-Arg-Val-Arg-
Arg-AMC for furin and 4 lM Boc-Val-Pro-Arg-AMC for matriptase
and HAT) (Bachem Bioscience, King of Prussia, PA, USA). Data from
three independent experiments or more were averaged and residual
velocities were plotted as a function of eglin c concentration. Data
were ﬁtted by non-linear regression analysis to the Eq. (1) [19] using
the Enzﬁtter software (Biosoft, Ferguson, MO, USA)
vi=vo ¼ 1 fð½E0 þ ½I0 þ K iðappÞÞ  ðð½E0 þ ½I0 þ K iðappÞÞ2
 4½E0½I0Þ1=2g=2½E0; ð1Þ
where v0 and vi are the steady-state rates of substrate hydrolysis in the
absence and presence of inhibitor, respectively, [E]0, the initial concen-
tration of enzyme, [I]0, the initial concentration of inhibitor and Ki(app)
the substrate-dependent equilibrium dissociation constant. The sub-
strate-independent constant Ki was calculated using the Eq. (2) [19],
K i ¼ K iðappÞð1þ ½S0=KmÞ; ð2Þ
where [S]0 is the initial concentration of substrate and Km the Michae-
lis–Menten constant for the enzyme–substrate interaction. To investi-
gate the stability of the eglin c variants, 4 lM of inhibitor was
incubated at room temperature with the indicated concentration ofmatriptase or HAT for the indicated time. Proteins were then resolved
by SDS–PAGE and revealed using the Gel Code blue stain reagent
(Pierce Biotechnology, Rockford, IL, USA).2.7. Molecular modeling
The complex between eglin c and matriptase was based on the exper-
imental structures of the chymotrypsin/eglin c complex (PDB ID-
1ACB) and of the matriptase/BPTI complex (PDB ID-1EAW). The
primary structures of matriptase (from 1EAW) and of chymotrypsin
(from 1ACB) were aligned with 43% identity. The structurally con-
served region (SCR) encompassing residues Ile16 and Cys58 of chymo-
trypsin and Val16 to Cys58 of matriptase (near the S1 subsite) showed
56% identity. 3D superimposition of this SCR gave a root mean square
deviation (RMSD) of 1.3064 A˚ between the Ca of both enzymes. The
overall structure is very similar for both enzymes and the residues
forming the catalytic triad (Ser195, His57 and Asp102) are positioned
in the matriptase active site exactly as in chymotrypsin. Superimposi-
tion of residues P3 to P4 0 of eglin c (i.e., Val43 to Tyr49, from
1ACB) and BPTI (Pro13 to Ile19, from 1EAW) gave a RMSD value
of 0.5073 A˚. Hence, the structures of matriptase (from 1EAW) and
eglin c (from 1ACB) were assembled into one complex, and hydrogen
atoms were added. This WT complex was subjected to 1000 steps of
energy minimization (all atoms were free to move) using conjugate gra-
dients (CG) with a dielectric value of 78. After the minimization pro-
cess, the RMSD between the heavy atoms of matriptase and the initial
1EAW structure was 1.2749 A˚ and between eglin c and the initial
1ACB structure was 0.8859 A˚. In order to study the eﬀect of mutations
at P1 and P4 0 positions, concerned residues were replaced in the model
(i.e., Leu45Arg, Tyr49Lys or Tyr49Glu) and each resulting complex
was subjected to another 1000 steps of minimization using CG. Molec-
ular rendering was realized with ribbons [20].3. Results
3.1. Expression, puriﬁcation and characterization of human
matriptase
The matriptase construct (amino acids 596–855) used in this
study encompassed the enzyme’s activation and catalytic do-
mains. The protease was expressed in E. coli as a His-tagged
fusion protein and was puriﬁed from denatured inclusion
bodies using IMAC. Denatured matriptase was then refolded
by a 2-step dialysis procedure to gradually remove the denatur-
ant. The refolded zymogen, which migrates at 29 kDa, was
capable of auto-activation as demonstrated by the decrease
in the size of the protein to 26 kDa (Fig. 1A and B). Fully ac-
tive matriptase was previously shown to occur from autopro-
teolytic cleavage of its activation domain [1].
Interestingly, the redox environment was important for
proper folding of matriptase. Addition of 1 mM b-mercap-
toethanol in the refolding buﬀer was essential to obtain a pro-
teolytically active protease (data not shown). The presence of
the activation domain was also a pre-requisite for the produc-
tion of an active protease. Thus, the expression and puriﬁca-
tion of a protein containing exclusively the catalytic domain
of matriptase (amino acids 615–855) produced an inactive en-
zyme (data not shown). To examine the pH proﬁle of the puri-
ﬁed enzyme, we assayed for matriptase activity between pH 6
and pH 11 using Boc-Glu-Ala-Arg-AMC as a substrate. The
results indicate that puriﬁed matriptase has optimal activity
from pH 9 to pH 11 (data not shown). In the ensuing experi-
ments, matriptase activity was measured at pH 9.3.2. Inhibition of recombinant matriptase by an eglin c variant
Furin has previously been shown to be inhibited by an eglin
c variant protein, R4R1-eglin, with substituted P42 and L45 for
Fig. 1. Expression of matriptase from E. coli during diﬀerent stages of
puriﬁcation. Expression of matriptase was induced in E. coli trans-
formed either with matriptase construct or empty pQE-30 vector with
0.5 mM IPTG for 3 h at 37 C. Samples for each step of puriﬁcation
(total proteins, inclusion bodies, renatured nickel-charged resin puri-
ﬁed proteins, mono-Q FPLC puriﬁed proteins) were resolved by SDS–
PAGE. (A) Coomassie blue staining of total proteins. (B) Western blot
analysis was performed with rabbit anti-human matriptase and donkey
anti-rabbit HRP antibodies (Bethyl laboratories, Montgomery, TX,
USA).
Fig. 2. Inhibition of matriptase by eglin c variants. (A) Amino acid
sequence of the ‘‘wild-type’’ eglin c protein (L1-eglin) used in this study
[14]. The protein is a product of a synthetic eglin c gene used to
optimize expression in E. coli. Reactive-site loop (P4 to P1) and
tyrosine-49 residue, corresponding to position P4 0, are shown in bold.
(B) Inhibition assay between matriptase and R4R1-eglin as described in
Section 2. (C) Matriptase inhibition by eglin c variants in a 96-well
plate. Each bar represents an eglin c variant with a residue in position
49 that has been randomly substituted for any one of the 20 possible
amino acids. The horizontal bar represents the level of inhibition by
R4R1-eglin. (D) Selected clones were identiﬁed by automated sequenc-
ing. Substitutions are identiﬁed below the clone number. Mat:
Matriptase activity without inhibitors. WT, level of matriptase
inhibition by wild-type eglin c. The horizontal bar represents the level
of inhibition by R4R1-eglin.
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tions, respectively, according to the nomenclature of Schechter
and Berger [21]) but not by wild-type eglin c (for amino acid
sequence see Fig. 2A) [14]. Incubation with R4R1-eglin abol-
ished matriptase activity while the wild-type eglin c had no ef-
fect (data not shown). To characterize the inhibition properties
of R4R1-eglin towards matriptase, inhibition assays were per-
formed and a Ki of 26 nM was determined (Fig. 2B and Table
1). R4R1-eglin was also a good inhibitor for furin with a Ki of
62 nM, but a weak inhibitor of human airway trypsin-like pro-
tease (HAT), another member of the TTSP family [22], with a
Ki > 1000 nM.
3.3. Optimization of matriptase inhibition by substitution of
position 49 of eglin c
Position 49 of eglin c, occupied by Tyr and corresponding to
the P4 0 position, had already been shown to be implicated in
the selectivity and aﬃnity of the inhibitor towards furin, PC7
and Kex2 [16]. In order to verify the eﬀect of the P4 0 position
on matriptase activity within a R4R1-eglin background, a
cDNA library of R4R1-eglin variants where each one of the
20 amino acids are substituted at position 49 was screened
for matriptase inhibition (Fig. 2C). Selected variants that ap-
peared to give enhanced, decreased or unchanged inhibition
relative to the control (R4R1-eglin) in an initial rapid screen
were sequenced at the nucleotide level (Fig. 2D). R4R1-eglin
variants that were found to give enhanced inhibition contained
an Arg or Lys at position 49 instead of the original Tyr resi-
due. Variants that showed no changes in matriptase inhibitioncontained either Ala, Leu or Tyr at position 49. Finally, the
two selected R4R1-eglin variants that showed decreased inhibi-
tion properties contained a Glu at position 49.
Ki values for the interaction between furin, matriptase or
HAT and three variants of R4R1-eglin substituted at position
49 were determined and compared (Table 1). R4R1K
0
4-eglin
exhibited a 4-fold higher aﬃnity for matriptase than R4R1-
eglin with a Ki of 6.1 nM. In contrast, substitution for Glu
in position 49 ðR4R1E04-eglinÞ resulted in an inhibitor exhibit-
ing an aﬃnity 5-times lower for matriptase than R4R1-eglin
with a Ki of 140 nM while R4R1R
0
4-eglin had a Ki of 11 nM.
These three eglin c variants appeared to be only weak inhibi-
tors of HAT (Ki > 1000 nM). In contrast to matriptase,
R4R1R
0
4-eglin but also R4R1E
0
4-eglin showed improved aﬃnity
for furin with Ki of 29 nM and 27 nM, respectively, while
R4R1K
0
4-eglin showed similar aﬃnity for furin with a Ki of
Table 1
Ki values for the diﬀerent eglin c variant proteins
Inhibitor Sequences P4–P
0
4 Ki (nM)
Furin Matriptase HAT
ﬂ
Eglin WT PVTLDLRY nd >1000 nd
R1-eglin PVTRDLRY >1000 18 420
R1K
0
4-eglin PVTRDLRK >1000 4.5 >1000
K2R1-eglin PVKRDLRY 630 930 >1000
R4R1-eglin RVTRDLRY 62 26 >1000
R4R1R
0
4-eglin RVTRDLRR 29 11 >1000
R4R1K
0
4-eglin RVTRDLRK 94 6.1 >1000
R4R1E
0
4-eglin RVTRDLRE 27 140 >1000
Eglin c variant proteins were obtained by substitution of residues
corresponding to amino acids 42–49 (P4–P40 position). Sequence for
each variant from amino acids 42–49 is indicated and substitution are
shown in bold. Ki values were determined as described in Section 2.
Values represent an average of at least three independent experiments.
Experimental errors were ±25 or less. ND, not determined (very weak
inhibitor).
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0
4-eglin was greatly enhanced
when compared to R4R1-eglin with a 15-fold higher selectivity
for matriptase than furin. Speciﬁcity of R4R1E
0
4-eglin was also
enhanced with a 5-fold higher selectivity for furin than matrip-
tase. These results indicate that the most selective and potent
eglin c variant is R4R1K
0
4 for matriptase.
3.4. Substitution within the reactive site loop of eglin c creates
variants with enhanced speciﬁcity and stability
We next decided to investigate whether amino acids inside
the reactive site loop of eglin c could be substituted to obtain
even more potent inhibitors of matriptase than R4R1K
0
4-eglin.
We tested the ability of R1-eglin (position P1) and K2R1-eglin
(position P2 and P1) to inhibit matriptase hydrolytic activity.
R1-eglin showed similar aﬃnity (18 nM) for matriptase than
R4R1-eglin while K2R1-eglin showed a dramatic decrease in
aﬃnity compared to R1-eglin or R4R1-eglin (Table 1). R1-eglinFig. 3. Susceptibility of the eglin c variants to matriptase cleavage. (A) 4 lM
for 5 h at 21 C before electrophoresis and revelation. [E]/[I] corresponds to
were incubated without () or with (+) 1 lM of matriptase for 5 h at 21 Chad a 23-fold higher aﬃnity for matriptase than HAT and was
a weak inhibitor of furin. Because the introduction of a lysine
instead of tyrosine in position 49 of the R4R1-eglin variant re-
sulted in an improved inhibitor for matriptase, we decided to
substitute the Tyr49 of R1-eglin for a lysine. The produced
R1K
0
4-eglin inhibitor, when compared to R1-eglin, showed a
4-fold enhanced aﬃnity for matriptase with a Ki of 4.5 nM.
R1K
0
4-eglin is only a weak inhibitor of furin and HAT (Ki of
>1000 nM) (Table 1).
Stability of the diﬀerent eglin c variants was investigated in
the presence of active matriptase. R4R1-eglin, K2R1-eglin,
R4R1K
0
4-eglin, R4R1R
0
4-eglin, R4R1E
0
4-eglin were all cleaved
when incubated with matriptase for 5-hour using an
enzyme:inhibitor ratio of 1:4 (Fig. 3A and B left panel). Con-
versely, R1K
0
4-eglin and R1-eglin showed virtually no cleavage
after a 5 h incubation under these conditions (Fig. 3B, right
panel). These results indicate that R1-eglin variants are better
inhibitors of matriptase than R4R1-eglin variants with equally
high aﬃnity but enhanced selectivity and stability. Overall,
R1K
0
4-eglin proved to be the best matriptase inhibitor with re-
gards to its aﬃnity, selectivity and stability.4. Discussion
Native and genetically engineered eglin c variants had previ-
ously been showed to be eﬃcient inhibitors of several serine
proteases including the human leukocyte elastase [23], chymo-
trypsin [24], trypsin [25] and members of the pro-protein con-
vertases family [14–16,26]. This inhibitor, as a member of the
potato inhibitor 1 family, has a ﬂexible reactive site loop that
increases its ability to adapt for enhanced interaction and inhi-
bition of new target enzymes [27,28]. Here we show that simple
substitutions in the reactive site loop of eglin c, yield high aﬃn-
ity inhibitors (low nanomolar) to matriptase. The simple intro-
duction of an arginine residue in the P1 position of the original
P4-P1 target sequence of eglin c, Pro-Val-Thr-Leu, trans-of R4R1-eglin was incubated with the indicated quantity of matriptase
the stoichiometric enzyme/inhibitor ratio. (B) 4 lM of eglin c variants
before electrophoresis and revelation.
Fig. 4. Molecular modeling of the matriptase/eglin c complex. (A) The matriptase structure is shown in white (faded to blue), whereas eglin c is in
dark gray. Oxygen atoms are shown in red, nitrogen in blue and hydrogen in cyan. Matriptase residues were numbered according to Friedrich et al.
[29]. Eglin c residues are underlined. (B–F) Close up on positions P1 and P4 0 of eglin c and their interacting counterparts in matriptase. (B) In the WT
eglin c, residue Leu45 forms favorable hydrophobic interactions with residues Tyr146, Val213 and Tyr228 at the S1 subsite of matriptase. (C) When
an Arg residue is present at P1, its charged guanidinium group forms a salt bridge with the carboxylate of Asp189 in S1. (D) The presence of the
negatively charged Glu residue at P4 0 impairs the formation of stabilizing hydrogen bonds with the backbone of Gln38-His40 in matriptase. Red bars
indicate unfavorable interactions. (E) In WT eglin c, the hydroxyl group of Tyr49 at P4 0 allows the formation of a stabilizing hydrogen bond with the
carbonyl of Gln38, which can be interchanged with the carbonyl of His40. Blue bars indicate favorable interactions. (F) Replacement of Tyr49 by a
Lys residue allows the formation of 2 stabilizing hydrogen bonds between the positively charged e-ammonium group and the backbone carbonyls of
Gln38 and His40. Blue bars indicate favorable interactions.
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tution at the P4 0 position yielded an even more potent inhibitor
of matriptase. The importance of the P4 0 position in the recog-
nition of eglin c by the members of the pro-protein convertases
family had been previously noted [16]. For matriptase, it is
very interesting to note that introduction of a basic residue
(arginine or lysine) at this position had a positive eﬀect on
the recognition of eglin c variants by matriptase while the
introduction of an acidic residue (glutamic acid) had a negative
eﬀect. The best inhibitor of matriptase in our study,
R1K
0
4-eglin, is also resistant to proteolysis which is not the case
for the R4R1-eglin variants. Thus, the R1K
0
4-eglin showed
remarkable inhibition characteristics with a high aﬃnity for
matriptase and high stability. We used molecular modeling
to gain insights into the eglin c’s structure-activity of positions
P1 and P4 0 with regards to matriptase (Fig. 4A-F). The S1 sub-
site of matriptase contains a few hydrophobic residues, namely
Tyr146, Val213 and Tyr228, which can form stabilizing inter-
actions with hydrophobic residue at P1 such as Leu45 in eglin c
(Fig. 4B). On the other hand, and as previously reported [29],
the presence of Asp189 within S1 allows the formation of a
favorable salt bridge with a positively charged residue at P1
(Fig. 4C). The favorable electrostatic interaction formed with
an Arg at P1 is more important in the stabilization energy of
the complex than the hydrophobic contacts observed with a
Leu residue at P1, leading in turn to a lower Ki for R1-eglin
mutant than for WT eglin c. Interactions between position
P4 0 of eglin c and matriptase are less speciﬁc as they involve
only backbone atoms of the enzyme. The complex is less stable
when Tyr49 is replaced by a negatively charged Glu residue,
because no favorable hydrogen bond can be formed with the
enzyme (Fig. 4D). The hydroxyl group of Tyr49 at P4 0 canform one hydrogen bond with the backbone carbonyl of either
Gln38 or His40 (Fig. 4E). Replacement of Tyr49 by a posi-
tively charged Lys residue allows the formation of two stabiliz-
ing hydrogen bonds with backbone carbonyls of Gln38 and
His40 and thus enhances stabilization of the complex com-
pared with WT eglin c (Fig. 4F).
Because of the suggested roles of matriptase in tumor inva-
siveness and metastasis, several groups have been interested in
the development of potent matriptase inhibitors through the
use of diﬀerent strategies, such as development of small mole-
cule inhibitors [30,31], mutation of the binding interface of
ecotin [32] and phage-displayed antibody library screening
[33]. Optimization of eglin c variants-matriptase contacts by
in vitro molecular evolution provides an additional strategy
to generate speciﬁc inhibitors of matriptase. TTSPs are an
expanding family of extracellular proteases and their speciﬁc
function is still poorly understood. Despite the fact that the
eglin c variants used in this study were not suitable inhibitors
of recombinant HAT, the use of an eglin c macromolecular
scaﬀold to produce speciﬁc inhibitors for other members of
the TTSPs could be envisioned. Eglin c inhibitors display inter-
esting characteristics in that they are small, make stable en-
zyme–inhibitor complexes and lack disulﬁde bridges for easy
expression in bacterial cultures. All these properties could
make them particularly useful tools in a diverse range of future
investigations, from the elucidation of matriptase’s physiolog-
ical function at the cell membrane to the potential production
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